이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Titan Pharmaceuticals 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

David Lazar

최고 경영자

US$1.5m

총 보상

CEO 급여 비율	27.6%
CEO 임기	1.9yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	1.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

David Lazar 의 보수는 Titan Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$1m	US$406k	-US$6m
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$726k	US$152k	-US$10m

보상 대 시장: David 의 총 보상 ($USD 1.47M )은 US 시장( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 David 의 보상이 증가했습니다.

CEO

David Lazar (33 yo)

1.9yrs

테뉴어

US$1,473,180

보상

Mr. David Elliot Lazar is Chief Business Development Officer of TRACON Pharmaceuticals, Inc. from May 7, 2024. He is Chairman and CEO of OpGen, Inc. from March 25, 2024. Mr. Lazar serves as Chief Executive...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Katherine Beebe-DeVarney	President	4.6yrs	US$602.11k	0.36% $ 17.6k
David Natan	Independent Director	1.9yrs	US$251.16k	0.36% $ 17.6k
Matthew McMurdo	Independent Director	1.9yrs	US$239.07k	0.36% $ 17.6k
Avraham Ben-Tzvi	Independent Director	1.9yrs	US$239.91k	0.36% $ 17.6k
Eric Greenberg	Independent Director	1.9yrs	US$244.07k	0.36% $ 17.6k
Brynner Chiam	Independent Director	less than a year	US$9.38k	데이터 없음
Gim Seow	Independent Chairman of the Board	less than a year	US$9.38k	0% $ 0

1.9yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: TTNP 의 이사회는 경험(평균 재직 기간 1.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Titan Pharmaceuticals 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024

High number of new and inexperienced directors

Titan Pharmaceuticals, Inc. Announces Board Resignations

Titan Pharmaceuticals, Inc. Announces Board Changes

Principal Executive Officer recently bought US$56k worth of stock

Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022

Recent updates

Titan Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $11 million.

Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024

Third quarter 2023 earnings released: US$0.023 loss per share (vs US$0.18 loss in 3Q 2022)

High number of new and inexperienced directors

Titan Pharmaceuticals, Inc. Announces Board Resignations

Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd

Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.18 loss in 2Q 2022)

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) for $52 million.

Titan Pharmaceuticals, Inc. Announces Board Changes

New major risk - Market cap size

Titan Pharmaceuticals Receives Extension Notice from the Listing Qualifications Department of the Nasdaq Notifying the Company an Additional 180-Day Period, or Until October 2, 2023 to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.24 loss in 1Q 2022)

Principal Executive Officer recently bought US$56k worth of stock

Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022

Less than half of directors are independent

Titan Pharmaceuticals, Inc. Announces Management Changes

Less than half of directors are independent

Titan Pharmaceuticals Announces Executive Changes

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.17 loss in 2Q 2021)

Activist Investing LLC Provides Information to the Shareholders

Is Titan Pharmaceuticals (NASDAQ:TTNP) In A Good Position To Invest In Growth?

Insider recently bought US$1.7m worth of stock

David E Lazar Sends a Letter to Titan Pharmaceuticals Inc

Titan Pharmaceuticals, Inc. Announces Fda Clearance of Ind Application for Nalmefene Implant

Insider recently bought US$348k worth of stock

First quarter 2022 earnings released: US$0.24 loss per share (vs US$0.28 loss in 1Q 2021)

Titan Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Insider recently bought US$157k worth of stock

Full year 2021 earnings released: US$0.90 loss per share (vs US$1.96 loss in FY 2020)

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.45 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$1.47 loss in 2Q 2020)

Titan Pharmaceuticals, Inc. Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

First quarter 2021 earnings released: US$0.28 loss per share (vs US$2.03 loss in 1Q 2020)

New 90-day low: US$2.88

Titan Pharmaceuticals, Inc. Announces Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with Its Jt-09 Proneura® Development Program

Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Titan Pharma regains Nasdaq listing compliance

Titan Pharmaceuticals announces 1-for-30 reverse stock split

Titan Pharmaceuticals, Inc., Annual General Meeting, Dec 30, 2020

Titan Pharmaceuticals EPS misses by $0.01, beats on revenue

Titan Pharma closes debt settlement and JT-09 acquisition

Titan Pharmaceuticals, Inc. has completed a Composite Units Offering in the amount of $11.44275 million.

Titan Pharma to raise $8M in stock offering

Titan Pharmaceuticals, Inc. Announces Executive Changes

Titan Pharmaceuticals, Inc. to Report Q3, 2019 Results on Nov 14, 2019

Analysts update estimates

New 90-day low - US$0.27

Earnings released

Titan Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 14, 2020

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령